Sign for Notice Everyday    注册| 登陆| 友情链接| English|

Our Sponsors


    26th Pharmacovigilance 2021 (Virtual Conference)

    View: 158

    Website https://www.virtueinsight.com/pharma/26th-Pharmacovigilance-2021-Virtual-Conference/ | Want to Edit it Edit Freely

    Category pharmacovigilance ; drug safety

    Deadline: November 10, 2021 | Date: November 11, 2021

    Venue/Country: Online Conference, India

    Updated: 2021-09-20 21:12:24 (GMT+9)

    Call For Papers - CFP

    26TH PHARMACOVIGILANCE 2021

    “Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management”

    11th November 2021, Virtual Conference (Time Zone – IST)

    Virtue insight’s 26th Pharmacovigilance Conference is more than a traditional conference. It is a unique opportunity to learn about the latest trends, to engage with renowned experts, and to personally develop as a healthcare professional. Take this opportunity to learn from regulators and leading experts and discover what the challenges and opportunities will be in the field of Pharmacovigilance in 2021. Do not miss out on these exciting discussions. Join us virtually to discover and learn from the experts who will be joining us on 11th November 2021.

    DELEGATE REGISTRATION:

    E-mail - kavithaatvirtueinsight.co.in or Call M: +91 9361957193 or +91 44 24762472

    Please note that this is a PAID event and NOT A FREE event (no complimentary passes available). Any invite, email or tickets issued mentioning it as a free pass or free ticket to this event through any third party site will strictly not be accepted by the organizer.

    Early Bird Price (Valid Till 27th September 2021)

    (INR 6,000 + GST (18%) per delegate)

    Standard Price (Valid From 28th September 2021)

    (INR 8,000 + GST (18%) per delegate)

    Conference Sponsor, Exhibition Stall & Paid Speaker Slot - Please email your interest and queries to kavithaatvirtueinsight.co.in

    KEY SPEAKERS:

    • K BANGARURAJAN, Adviser, CDSCO (New Delhi)

    • KHAUDEJA BANO, Executive Medical Director, Combination Product Safety Head, Amgen (USA)

    • SUMIT MUNJAL, Vice President, Global Patient Safety Evaluation, Takeda (Belgium)

    • KLAUDIJA MARIJANOVIC BARAC, Sr Director, Global Patient Safety & PhV, Teva(UK)

    • ROHAN MANE, Director, Risk Management Product Lead, Pfizer (UK)

    • TEA BABIC, Director, PV Audits and Inspections, Teva Pharmaceuticals (UK)

    • MAHESH MURTHY, Sr. Director of Operations - Medical Device, Biocon

    • SUBHASH C MANDAL, Vice President and Chairman, Regulatory Affairs Division, Indian Pharmaceutical Association

    • ANIL KUKREJA, Vice President - Medical Affairs and Regulatory, AstraZeneca

    • NISHITH TYAGI, Director (Data Science and AI Solutions), Novartis

    • PRAVEEN RAJ, Senior Director Medical Affairs, Biocon

    • RAJEEV SHRIVASTAVA, Associate Director -Regulatory Affairs and Pharmacovigilance, Eli Lilly

    • VAIBHAV CHOUDHARY, Associate Director Global Medical, Clinical & Regulatory Affairs, Fresenius Kabi

    • KAVITA LAMROR, Director, Real World Investigator, Sanofi

    • KARTHIKEYAN KUMARAN, Associate Director of Information Technology, AstraZeneca

    • MILIND ANTANI, Leader, Pharma and Healthcare, Nishith Desai Associates

    • DNYANESHWAR SANAP, EU/UK QPPV, Head Regional Pharmacovigilance, Glenmark (Germany)

    • AVINASH R. KAKADE, SGM, Global Head –Pharmacovigilance, Lupin

    • VEENA RAJAN, Head Mature Products PV, Global Patient Safety, AstraZeneca

    • JAIDEEP GOGTAY, Chief Medical Officer, Cipla

    • GEETA SHANBHAG, Sr. General Manager –Pharmacovigilance & Medico-regulatory Affairs, Ipca Laboratories

    • JYOTSNA PATWARDHAN, Cluster Head, PV Country Quality, Novartis

    • JAMAL ANWAR, Country Head Pharmacovigilance, Merck Sharp and Dhome

    • INDU NAMBIAR, Head Pharmacovigilance, Boehringer Ingelheim

    • VALLABH DESHPANDE, Head of Global PV Operations, Glenmark

    • VISHWAS SOVANI, Founder Director, Pharamwisdom

    • RAJENDRA KUMAR KASI, Head - Global Pharmacovigilance, Zydus Cadila Healthcare

    • ROSHAN PAWAR, Associate General Manager, Alkem Laboratories

    • RAGHDA MOHAMED, PV Cluster Lead Middle East & Turkey, Takeda (UAE)

    • VARSHA NARAYANAN, Founder-Director, Dr Varsha’s Health Solutions

    • SAKSHI SHRIVASTAVA DESAI, Global Medical- PV Compliance Strategy and Analytics, Johnson & Johnson

    • GAYATHRI DEVI RAVICHANDRAN, Associate Manager - Regional Safety Operations, Merck

    • KAVYA KADAM, Consultant, Global Clinical Trials

    Plus more joining soon

    WHO SHOULD ATTEND AND WHO YOU’LL MEET:

    CIOs, CEOs, CDOs, Vice Presidents, Presidents, Heads, Directors and Team Leaders from the following areas:

    Pharmacovigilance Strategy, Drug Safety/Risk Management, Information and Clinical Data Management, Clinical Research, Research & Development, Product Safety/Assurance Assessment, Patient Safety & Outcomes Research & Data Analysis, Epidemiology project management, Regulatory Affairs and Compliance, Sales & Marketing, Biotech manufacturers

    From the following:

    Pharmaceutical organizations, Generic pharmaceutical companies, Contract research organizations, Patient recruitment companies, Government- Department of health, Non-profit organizations/ Association, Consultants

    Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking time, meet the leading international vendors showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference.


    Keywords: Accepted papers list. Acceptance Rate. EI Compendex. Engineering Index. ISTP index. ISI index. Impact Factor.
    Disclaimer: ourGlocal is an open academical resource system, which anyone can edit or update. Usually, journal information updated by us, journal managers or others. So the information is old or wrong now. Specially, impact factor is changing every year. Even it was correct when updated, it may have been changed now. So please go to Thomson Reuters to confirm latest value about Journal impact factor.